Charles Riv­er cuts the rib­bon on for­mer As­traZeneca site in the UK for plas­mid man­u­fac­tur­ing

Af­ter start­ing con­struc­tion last year and putting the fin­ish­ing touch­es on the site this year, Charles Riv­er is fi­nal­ly ready to cut the rib­bon on a new 16,000-square-foot fa­cil­i­ty across the At­lantic.

The man­u­fac­tur­ing fa­cil­i­ty will pro­duce plas­mids to be used in cell and gene ther­a­pies. The site, lo­cat­ed in Cheshire, UK, is the re­sult of Charles Riv­er’s ac­qui­si­tion of Cog­nate BioSer­vices and Co­bra Bi­o­log­ics in 2021 for $875 mil­lion last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER